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Syk is a non-receptor tyrosine kinase critically involved in signaling by various
immunoreceptors including B-cell-receptors and activating Fc-receptors. We have
previously shown that Syk also mediates immunoreceptor-like signals required for the
in vitro development and function of osteoclasts. However, the perinatal lethality of
Syk−/− mice precluded the analysis of the role of Syk in in vivo bone metabolism.
To overcome that problem, we generated mice with osteoclast-specific (Syk1OC) or
hematopoietic (Syk1Haemo) Syk deficiency by conditional deletion of Syk using Cre
recombinase expressed under the control of the Ctsk or Vav1 promoter, respectively.
Micro-CT analysis revealed increased bone trabecular density in both Syk1OC and
Syk1Haemo mice, although hematopoietic Syk deficiency caused a more severe
phenotype than osteoclast-specific Syk deficiency. Osteoclast-specific Syk deficiency
reduced, whereas hematopoietic Syk deficiency completely blocked in vitro development
of osteoclasts. Both interventions inhibited the resorptive activity of osteoclasts and
osteoclast-specific gene expression. Kinetic analysis of Syk protein levels, Cre expression
and the genomic deletion of the Sykflox allele revealed complete and early deletion of Syk
from Syk1Haemo osteoclasts whereas Syk was incompletely deleted at a later stage of
osteoclast development from Syk1OC cultures. Those results provide an explanation for
the in vivo and in vitro difference between the Syk1OC and Syk1Haemo mutant strains and
suggest late activation of, and incomplete target gene deletion upon, osteoclast-specific
Cre expression driven by the Ctsk promoter. Taken together, our results indicate that Syk
plays an indispensable role in osteoclast-mediated in vivo bone resorption and suggest
that Syk-specific inhibitors may provide therapeutic benefit in inflammatory and other
diseases characterized by excessive osteoclast-mediated bone resorption.
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INTRODUCTION
Osteoclasts are multinuclear giant cells of hematopoietic
origin which develop from myeloid progenitors through a
unique biochemical maturation program followed by homotypic
fusion (1, 2). Osteoclasts are the sole cell types in the
mammalian organism capable of actively resorbing bone tissue
and therefore play a critical role in bone homeostasis. Defective
osteoclast development or function leads to increased bone
mass (osteopetrosis) (3), whereas excessive (pathological) bone
resorption occurs during osteoporosis (4), inflammatory joint
diseases (e.g., arthritis-induced bone erosions in rheumatoid
arthritis) (5, 6) and cancer-induced bone loss (7, 8).
Osteoclast development and function requires a number of
extracellular cues including M-CSF, RANKL, as well as integrin-
mediated adhesive processes (9). The importance of those
pathways is indicated by the severe bone resorption defects in
mice lacking M-CSF (10), RANK (11, 12), RANKL (13, 14), or
β3 integrins (15). Culturing myeloid progenitors derived from
human blood or mouse bone marrow in the presence of M-
CSF and RANKL also leads to formation of osteoclast-like cells
with in vitro bone resorbing capacity, allowing the analysis of
osteoclast development and function in cell culture.
Syk is a non-receptor tyrosine kinase critically involved in
various functions of the immune system, as well as certain non-
immune-related biological processes (16). Syk is required for B-
cell-receptor signaling and therefore the development of B-cells
(17, 18). It is a critical component of signaling by a number of
activating Fc-receptors such as Fcε-receptors and Fcγ-receptors
on neutrophils, macrophages, and mast cells (19–22), as well
as the Fc-receptor-related collagen receptor GpVI of platelets
(23, 24). Syk also mediates signaling by β1, β2, and β3 integrins in
neutrophils, monocytes/macrophages, and platelets (25–27). Syk
deficiency causes perinatal lethality (17, 18) likely due to the role
of Syk in lymphatic vascular development (28). Most, if not all
of those functions of Syk is related to its binding to receptor-
associated tyrosine-phosphorylated immunoreceptor tyrosine-
based activation motifs (ITAMs) linking immunoreceptors to
downstream signaling pathways (16, 29–32). The role of Syk
in various immune and inflammatory processes also translates
into its role in autoantibody-induced arthritis (24, 33–35) and
dermatitis (36, 37) in experimental mice.
We and others have previously shown that the ITAM-
containing adapter molecules DAP12 and FcRγ are involved
in in vitro osteoclast development and function, and that
mice lacking both DAP12 and FcRγ show strongly increased
mineralized bone mass (38–43). One of the possible mechanisms
for those phenotypes could be that, similar to immune cells
(16, 29), the ITAM-containing DAP12 and FcRγ adapters would
activate the Syk tyrosine kinase in osteoclasts, thus triggering
osteoclast development and function. Indeed, Syk-deficient
bone marrow cells failed to develop to mature multinucleated
osteoclasts or to show resorptive activity in in vitro cultures
(40, 42, 44, 45), and this in vitro phenotype was linked to ITAM
signaling by DAP12 and FcRγ (42–44). Those studies provided
an unexpected link between immunoreceptor-like signaling and
bone homeostasis and therefore provided one of the foundations
of the field of osteoimmunology (46, 47). In addition, Syk-
mediated pathways have also been linked to integrin signal
transduction and the osteoclast cytoskeleton (16, 26, 42, 44, 48).
Unfortunately, however, it is at present unclear whether Syk
is also involved in bone homeostasis in live animals, as bone
morphology of Syk-deficient animals could not be tested because
of the perinatal lethality of Syk−/− mice (17, 18).
To overcome the perinatal lethality of Syk−/− animals, we
have generated mice with osteoclast-specific or hematopoietic-
specific Syk deletion using the Cre-Lox recombination approach.
Analysis of the mice with tissue specific Syk deletion revealed
strong increase in bone mass upon osteoclast-specific and,
particularly, hematopoietic-specific Syk-deficiency, indicating a
critical role for Syk in in vivo bone homeostasis. Further
experiments aimed at understanding the different severities of
the bone phenotypes in the two strains indicated that the effect
of Syk deficiency on osteoclast development strongly depends
on the timing and extent of Cre expression and Cre-mediated
inactivation of the Syk gene.
MATERIALS AND METHODS
Animals
Mice carrying the Syktm1.2Tara (referred to as Sykflox) floxed allele
of the Syk gene (49) were obtained from Alexander Tarakhovsky
(Rockefeller University) and were maintained in homozygous
(Sykflox/flox) form. Mice carrying the Ctsktm1(cre)Ska (referred to
as CtskCre) knock-in mutation resulting in the osteoclast-specific
expression of the Cre recombinase under the control of the
endogenous promoter of the Ctsk gene and at the same time
inactivating the Ctsk gene (50) were obtained from Shigeaki
Kato (University of Tokyo) and were maintained in heterozygous
form (referred to as Ctsk-Cre) to avoid homozygous inactivation
of the Ctsk gene. Mice carrying the Commd10Tg(Vav1−icre)A2Kio
transgenic insertional mutation expressing the Cre recombinase
in the entire haemopoietic lineage from the exogenous Vav1
promoter (51) and at the same time inactivating the Commd10
gene (52) were obtained from the Jackson Laboratory and were
maintained in heterozygous form (referred to as Vav-Cre) to
avoid homozygous inactivation of the Commd10 gene. Mice
carrying the Lyz2tm1(cre)Ifo (referred to as Lyz2Cre) knock-in
mutation expressing the Cre recombinase in the entire myeloid
compartment from the endogenous promoter of lysozyme M
(53) were purchased from the Jackson Laboratory and were
maintained in homozygous form (referred to as LysM-Cre).
Osteoclast-specific deletion of Syk was achieved by
crossing the Ctsk-Cre and Sykflox/flox mice to obtain
CtskCre/+Sykflox/flox (referred to as Syk1OC) animals.
Deletion of Syk in the entire hematopoietic compartment
was achieved by crossing the Vav-Cre and Sykflox/flox mice
to obtain Commd10Tg(Vav1−icre)A2Kio/+Sykflox/flox (referred to
as Syk1Haemo) animals. Myeloid-specific deletion of Syk was
achieved by crossing the LysM-Cre and Sykflox/flox mice to obtain
Lyz2Cre/CreSykflox/flox (referred to as Syk1Myelo) animals. The
allele obtained by Cre-mediated deletion of the Sykflox allele will
be referred to as the Syk1 allele.
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Genotyping of the mice was performed by allele-specific
PCR. All mice were on the C57BL/6 genetic background.
Wild type C57BL/6 animals were obtained from our breeding
colony. The mice were kept in individually sterile ventilated
cages (Tecniplast) in a specific pathogen-free facility. All animal
experiments were approved by the Animal Experimentation
Review Board of Semmelweis University.
Micro-CT Analysis
Mice were sacrificed at 9 weeks of age and their right femurs
were subjected to micro-CT analysis by a SkyScan 1172 micro-
CT apparatus as described (54, 55). A 70 kV and 124 µA
X-ray source with 0.5mm aluminum filter and a rotation
step of 0.5◦ was used during image acquisition, followed by
reconstruction with the SkyScan NRecon software, resulting in
an isometric 5µm voxel size. Volume of interest was selected
according to the manufacturer’s instructions. Further analysis
was performed using the Skyscan CTAn and CTVol software.
The lower threshold of binary images was set to an absolute value
of 85 throughout the entire study. Our study design did not allow
the calculation of absolute bone hydroxyapatite densities.
Quantitative analysis was performed on the trabecular
region of the distal femoral metaphysis beginning 50 sections
(0.25mm) from the distal growth plate to an additional 400
sections (2mm) to the proximal direction, including the entire
trabecular area within that range, identified manually by visual
inspection. Quantitative parameters included percent bone
volume (BV/TV), trabecular number, trabecular thickness and
trabecular separation as described (54, 55).
Representative cross sections represent the 200th section
(1mm) from the distal femoral growth plate. 3D images show an
axial cylinder of a diameter of 500µm between sections 150–450
from the distal growth plate.
Histological Procedures and
Immunostaining
Femurs isolated from mice at 9 weeks of age were fixed in 4%
paraformaldehyde (Sigma-Aldrich) followed by decalcification
in Osteomoll (Merck) for 3 weeks. The samples were then
dehydrated, and embedded in paraffin (Leica) using a Leica
EG1150H embedding station. Eight micrometers of thick
sections were obtained using a Thermo Scientific HM340E
microtome and were processed for hematoxylin and eosin (Leica)
staining, or for immunostaining for the calcitonin receptor
using anti-Calcitonin Receptor (Abcam AB11042) and anti-
rabbit Alexa Fluor 488 (Life Technologies, A11034) antibodies.
Microscopic images were taken by a Nikon ECLIPSE Ni-U
microscope connected to a Nikon DS-Ri2 camera.
In vitro Culture and Resorption Assays
In vitro osteoclast cultures were performed essentially as
described before (54, 55). Bone marrow cells obtained by flushing
the tibia and femur of wild type or mutant mice were cultured
in the presence of 10 ng/ml murine M-CSF (Peprotech) for 2
days in α-MEM medium (Sigma) supplemented with 10% FCS
(Gibco) and antibiotics. Non-adherent cells were then plated at
the concentration of 1.5 × 105 cells/cm2 and cultured in the
presence of 50 ng/ml recombinant murine M-CSF and 50 ng/ml
murine RANKL (Peprotech) with medium changes every 2 days.
In parallel macrophage cultures, the cells were cultured under
identical conditions except that RANKL was omitted.
Cultures were terminated and osteoclast-specific staining
was performed using a commercial tartrate-resistant acid
phosphatase (TRAP) staining kit (Sigma-Aldrich) at
the indicated times after the first addition of RANKL.
Photomicrographs were taken using a Leica DMI6000B
inverted microscope. The images were then analyzed either
manually or by the ImageJ software. Osteoclasts were defined as
TRAP-positive cells with 3 or more nuclei.
For in vitro resorption assays, osteoclasts were cultured under
similar conditions for 7 days on an artificial hydroxyapatite
surface (Sigma-Aldrich) followed by washing, imaging by dark
field microscopy and further analysis by ImageJ software.
Biochemical Studies
For protein content analysis, osteoclast, or macrophage
cultures were washed and then lysed in a Triton-based lysis
buffer containing 100mM NaCl, 30mM Na-HEPES (pH
7.4), 20mM NaF, 1mM Na-EGTA, 1% Triton X-100, 1mM
benzamidine, freshly supplemented with 0.1 U/ml Aprotinin,
1:100Mammalian Protease Inhibitor Cocktail, 1:100 Phosphatase
Inhibitor Cocktail 2, 1mM PMSF, and 1mM Na3VO4 (all from
Sigma-Aldrich). Insoluble material was removed, the lysate
supernatants were supplemented with 4× Laemmli’s sample
buffer and boiled for 10min. Whole cell lysates were run on
SDS-PAGE, electroblotted to nitrocellulose membranes, and
then processed for immunoblotting with antibodies against Syk
(N19; Santa Cruz) or β-actin (Clone AC-74; Sigma-Aldrich).
After incubation with peroxidase-labeled secondary antibodies
(GE Healthcare), the signal was developed using the ECL system
(GE Healthcare) and exposed to X-ray film. X-ray films were
then scanned and processed with Adobe Photoshop.
Quantitative RT-PCR Analysis
To test osteoclast specific and Cre gene expression changes,
mouse myeloid progenitors were differentiated into osteoclasts
or macrophages in the presence of 50 ng/ml M-CSF with or
without 50 ng/ml RANKL for 0–3 days, followed by RNA
extraction and reverse transcription as previously described
(54–56). For quantitative reverse transcription (RT)-PCR
analysis of the osteoclast-specific genes, the following TaqMan
assays were used: Acp5 (TRAP; TaqmanMm00475698_m1), Ctsk
(cathepsin K; Mm00484039_m1), Calcr (Calcitonin receptor;
Mm00432271_m1), Nfatc1 (NFATc1; Mm00479445_m1),
and Tm7sf4 (DC-STAMP; Mm04209235_m1) as previously
described (54, 55). For assessment of Cre expression,
the 5′- TGACGGTGGGAGAATGTTAATC forward and
5′ GCTACACCAGAGACGGAAATC reverse primers were used.
Transcript levels relative to GAPDH were calculated using the
comparative Ct method (54, 55).
Sequencing of the Germline Sykflox Allele
To determine the exact sequence of the Sykflox allele, tail DNA
was amplified using the 5′- GCC CGT TCT GTG CCT ACT
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GG−3′ forward and 5′- TAG CTA ACC AAA CCC ACG GC−3′
reverse primers spanning the 5′ loxP site, or the 5′- CCA AAG
CGG AGT CCT CAC AT−3′ forward and 5′- GTC GGT CCC
ATC TTT CC−3′ reverse primers spanning the 3′ loxP site. PCR
products were then sent to Microsynth for sequencing and the
obtained sequences were aligned with the genomic sequence of
the wild type Syk gene to obtain the sequence of the Sykflox allele.
Genomic PCR Analysis
Osteoclast cultures were washed at the indicated times after the
start of RANKL treatment, followed by isolation of genomic DNA
and PCR using standard procedures.
Two different PCR assays were performed on the genomic
DNA of osteoclast cultures. In PCR 1, the 5′- GCC CGT TCT
GTG CCT ACT GG−3′ forward primer (P fwd) was used along
with the 5′- TAG CTA ACC AAA CCC ACG GC−3′ reverse
primer (P rev1) to separate the Syk+ and Sykflox alleles (234 and
349 bp product length, respectively). In PCR 2, the same P fwd
forward primer was used with the 5′- GTC GGT CCC ATC TTT
CC−3′ reverse primer (P rev2) to separate the Syk+, Sykflox and
Syk1 alleles (1314, 1560 and 452 bp product length, respectively).
Statistical Analysis
Experiments were performed the indicated number of times.
Diagrams show mean and SEM from the indicated number
of independent experiments. Micro-CT measurements
were analyzed by two-way (factorial) ANOVA with the
presence/absence of Cre and the Syk genotype as the independent
parameters. Other measurements were analyzed by one-way
ANOVA followed by Tukey or Unequal n HSD post hoc test. In
case of the kinetic analysis of osteoclast morphology, statistical
analysis was performed on the area under the curve (AUC).
P-values below 0.05 were considered statistically significant.
RESULTS
The Effect of Osteoclast-Specific Syk
Deletion on Trabecular Bone Architecture
The Syk−/− mutation causes perinatal lethality making it
technically impossible to analyze the bone morphology of
adult Syk−/− mice. We decided to overcome that problem
by generating lineage-specific Syk-deficient animals. As a first
approach, we crossed mice in which the cDNA of the Cre
recombinase has been inserted into the osteoclast-specific Ctsk
gene (referred to as CtskCre/+ or Ctsk-Cre mice) (50) with mice
carrying a floxed Syk allele (referred to as Sykflox/flox mice) (49).
The resulting CtskCre/+Sykflox/flox (referred to as Syk1OC) mice
are expected to have defective Syk expression in osteoclasts due
to Cre-mediated excision and inactivation of the Syk gene.
We then subjected Syk1OC mice and the appropriate controls
to micro-CT analysis of the distal femur. As shown in the
longitudinal sections of the femurs of female mice in Figure 1A,
the Syk1OC mutation strongly increased the density of the
trabecular area compared to wild type mice, whereas no dramatic
difference could be observed in Ctsk-Cre or Sykflox/flox animals.
Analysis of representative cross-sections of male or female mouse
femurs also showed increased trabecular density in Syk1OC but
not in Ctsk-Cre or Sykflox/flox animals, particularly in the case
of female mice (Figure 1B). The increased trabecular density
was also evident in three-dimensional reconstitution of an axial
cylinder within the trabecular area of the femurs (Figure 1C).
We also processed micro-CT images for quantitative analysis,
incorporating data from the entire trabecular space within a
defined distance range from the distal femoral growth plate.
As shown in Figure 2, the percent bone volume (BV/TV) was
strongly increased in Syk1OC mice, whereas no substantial
difference could be observed in Ctsk-Cre or Sykflox/flox mice.
Male wild type mice had an ∼2.8-fold higher (10.8%) basal
percent bone volume (BV/TV) than their female counterparts
(3.9%). However, the increase in BV/TV in Syk1OC over wild type
mice was more robust in female (4.4-fold) than in male (1.8-fold)
animals (Figure 2). We have also performed statistical analysis
by two-way (factorial) ANOVA which determines the interaction
of the two (Ctsk-Cre and Sykflox/flox) mutations, i.e., whether the
co-existence of the two mutation in the Syk1OC resulted in a
statistically significant difference beyond an additive effect. That
analysis revealed a significant increase of the BV/TV values both
in male (p= 0.028) and, especially, in female (p= 0.00005) mice.
Further quantitative (Figure 2) and statistical (two-way
ANOVA) analysis of the trabecular bone revealed a higher
trabecular number in Syk1OC mice (p = 0.0069 and 0.00001 for
males and females, respectively), whereas no consistent change
was observed in the trabecular thickness of the same animals (p=
0.85 and 0.87 for males and females, respectively). In agreement
with the increased trabecular number, trabecular separation was
reduced in Syk1OC mice (p = 0.00032 and 0.0011 for males and
females, respectively).
Taken together, our results indicate that osteoclast-specific
deletion of Syk causes increased bone trabecular mass primarily
due to increased bone trabecular number rather than a higher
trabecular thickness. However, the phenotype observed in
Syk1OC mice (Figure 2) appeared to be less dramatic than
that reported for Tyrobp−/−Fcer1g−/− double knockout mice
lacking both the DAP12 and FcRγ ITAM-containing adapter
molecules which were previously proposed to signal through
Syk (42, 43, 57).
The Effect of Hematopoietic Deletion of
Syk on Trabecular Bone Architecture
The apparently less severe bone phenotype of Syk1OC mice
compared to Tyrobp−/−Fcer1g−/− (DAP12/FcRγ double
knockout) animals (42, 43, 57) could either be due to a less
critical role for Syk in in vivo bone homeostasis or the less
complete deletion of Syk in Syk1OC animals. To test this latter
possibility, we turned to mice with Syk deficiency in the entire
hematopoietic compartment due to deletion by the Vav-Cre
transgene which causes Cre expression during the early stages
of hematopoiesis (51). Accordingly, we subjected Vav-Cre
Sykflox/flox (referred to as Syk1Haemo) mice and appropriate
controls to microCT analysis of the distal femur.
As shown in Figure 3A, Syk deletion in the entire
hematopoietic compartment by the Syk1Haemo mutation
caused a very strong increase in trabecular density in the
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FIGURE 1 | Micro-CT analysis of osteoclast-specific Syk-deficient mice. Representative micro-CT images of the femurs of 9-week-old mice of wild type (WT) and the
indicated mutant mice. (A) Longitudinal sections of the femur of female mice. (B) Cross-sections of the femur of male or female mice. (C) 3D reconstitution of an axial
cylinder of the trabecular area of the distal metaphysis of femurs of male or female mice. Images are representative of micro-CT analysis of 5 mice per gender and
genotype.
longitudinal sections of the femurs of female animals, whereas
no substantial changes were observed in Vav-Cre or Sykflox/flox
mice. An increased trabecular density in Syk1Haemo mutants
could also be observed in cross-sections of the distal femurs
of male and, in particular, female mice, whereas no obvious
differences could be seen in Vav-Cre or Sykflox/flox animals
(Figure 3B). Three-dimensional reconstitution of a trabecular
area cylinder also showed visible increases in the trabecular
density in Syk1Haemo animals (Figure 3C).
Further quantitative analysis of the microCT data (Figure 4)
indicated a strongly increased percent bone volume (BV/TV)
in Syk1Haemo mice in both male and female animals.
Importantly, BV/TV values in Syk1Haemo mice appeared to
be substantially higher than corresponding Syk1OC animals
(compare Figures 2, 4). On the other hand, similar to the
Syk1OC results, the BV/TV fold increase in Syk1Haemo over
wild type animals was higher in females (7.9-fold) than in males
(4.0-fold), again primarily due to the higher basal values in
male wild type mice. Statistical analysis by two-way ANOVA
revealed a highly significant interaction between the effects of the
Vav-Cre and Sykflox/flox mutations (p = 0.00032 and 0.00003 for
males and females, respectively), indicating that Cre-mediated
deletion of Syk in Syk1Haemo mice strongly increases trabecular
bone mass.
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FIGURE 2 | Quantitative micro-CT analysis of osteoclast-specific Syk deficiency. The right femurs of 9-week-old wild type (WT) or the indicated mutant male or female
mice were subjected to micro-CT analysis, followed by quantification of percent bone volume (bone volume/total volume, BV/TV), trabecular number, trabecular
thickness and trabecular separation. The graphs show mean and SEM of data obtained from 5 mice per gender and genotype.
Further quantitative assessment (Figure 4) and statistical
analysis (two-way ANOVA) revealed that, similar to the Syk1OC
mice, the increased trabecular bone volume was primarily due
to an increased trabecular number (p = 0.0010 and 0.00001
for males and females, respectively), rather than significant
changes in trabecular thickness (p = 0.31 and 0.61 for males and
females, respectively). Trabecular separation was also reduced
in Syk1Haemo mice (p = 0.0045 and 0.0071 for males and
females, respectively).
Taken together, early deletion of Syk in the entire
hematopoietic system results in dramatic increase in the
mineralized trabecular bone mass, indicating a critical role
for Syk in in vivo bone homeostasis. The bone phenotype
seen in Syk1Haemo mice is grossly comparable to that reported
for Tyrobp−/−Fcer1g−/− (DAP12/FcRγ double knockout)
animals (42, 43, 57), raising the possibility that the majority
of DAP12/FcRγ signals proceeds through Syk in live mice.
However, the 30–45% BV/TV values observed in Syk1Haemo
mice are substantially higher than the corresponding values
(15–20%) in Syk1OC animals, raising the possibility that the
lower values in the latter mutants may be due to incomplete
deletion of Syk by Cre expression from the Ctsk-Cre mutation.
Bone Histological Analysis
We have also performed histological analysis of the distal femur
of wild type, Syk1OC or Syk1Haemo mice. As shown in Figure 5A,
a much more dense trabecular network was seen in Syk1OC and,
especially, Syk1Haemo mice than in wild type animals. Again, the
difference was more pronounced in female mice because of the
lower trabecular density in female than in male mice in the wild
type cohorts.
To test the presence of mature osteoclasts on the trabecular
bone surface, we have performed immunofluorescence staining
of bone sections for calcitonin receptor, an osteoclast-specific
differentiation marker. As shown in Figure 5B, calcitonin
receptor signals were evident on the lining of trabecular rods
(dark areas) in wild type sections. Similar signals were also seen
but at substantially lower numbers in Syk1OC sections, whereas
no such signals were seen in Syk1Haemo sections (Figure 5B).
Those results suggest that the number of calcitonin receptor-
positive osteoclasts is reduced in Syk1OC and, especially, in
Syk1Haemo mice.
In vitro Osteoclast Development in
Lineage-Specific Syk Mutants
We next tested in vitro development of osteoclasts from wild
type, Syk1OC or Syk1Haemo bone marrow cells in the presence
of recombinant M-CSF and RANKL cytokines. Bone marrow
cells were first cultured for 2 days in low (10 ng/ml) M-CSF
and non-adherent cells (referred to as myeloid progenitors) were
then cultured in the presence of 50 ng/ml M-CSF and 50 ng/ml
RANKL. Osteoclast development was then tested by assessing
cell morphology and positive histochemical staining for the
osteoclast-specific TRAP enzyme.
As shown in Figure 6A, no TRAP-positive multinuclear cells
(osteoclasts) were seen 2 days after addition of RANKL to
the cultures. However, osteoclasts started to appear in wild
type cultures on day 3 and formed very large multinucleated
TRAP-positive cells 3.5 days after the initial RANKL treatment.
Some osteoclasts also formed in Syk1OC cultures, though
they were much smaller in size and failed to fuse into
very large cells even by 3.5 days after RANKL treatment
(Figure 6A). On the other hand, practically no osteoclasts
(multinucleated TRAP-positive cells) could be observed in
Syk1Haemo cultures (Figure 6A).
We have also quantitated the extent of in vitro osteoclast
formation. To this end, we have counted the number of
osteoclasts (defined as TRAP-positive cells with 3 or more
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FIGURE 3 | Micro-CT analysis of hematopoietic Syk-deficient mice. Representative micro-CT images of the femurs of 9-week-old mice of wild type (WT) and the
indicated mutant mice. (A) Longitudinal sections of the femur of female mice. (B) Cross-sections of the femur of male or female mice. (C) 3D reconstitution of an axial
cylinder of the trabecular area of the distal metaphysis of femurs of male or female mice. Images are representative of 5–7 mice per gender and genotype. WT
samples are identical to those shown in Figure 1.
nuclei; Figure 6B) and calculated the percent of the culture
area covered by the osteoclasts (Figure 6C). Though the two
different quantification approaches were related to each other,
they also complemented each other, since later stages of osteoclast
development may lead to the emergence of very large osteoclasts
which occupy large culture areas but are small in numbers (as
seen in the last two images in wild type cultures in Figure 6A).
As seen in Figures 6B,C, there were practically no osteoclasts
in any of the cultures 2 days after the initial RANKL addition.
However, osteoclasts rapidly emerged afterwards in wild type
cultures, reaching a maximum number 1 day later. The area
covered by wild type osteoclasts increased further in the next
12 h, even though the number of osteoclasts started to decline,
indicating the fusion of the cells into a few very large osteoclasts
in this final stage of osteoclast development (Figures 6B,C).
The number of osteoclasts also increased in Syk1OC cultures
and was temporarily even comparable to that of wild type
osteoclasts (Figure 6B). However, those Syk1OC osteoclasts
covered a significantly smaller area than in wild type cultures
throughout the experiments (Figure 6C), which was in line
with the smaller size of Syk1OC osteoclasts in Figure 6A. On
the other hand, again in agreement with the photomicrographs
in Figure 6A, practically no osteoclasts could be identified in
Syk1Haemo cultures (Figures 6B,C).
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FIGURE 4 | Quantitative micro-CT analysis of hematopoietic Syk deficiency. The right femurs of 9-week-old wild type (WT) or the indicated mutant male or female
mice were subjected to micro-CT analysis, followed by quantification of percent bone volume (bone volume/total volume, BV/TV), trabecular number, trabecular
thickness and trabecular separation. The graphs show mean and SEM of data obtained from 5–7 mice per gender and genotype. WT values are identical to those
shown in Figure 2.
We have also performed more detailed statistical analyses
(one-way ANOVA) of the area under the curve (AUC) from
data presented in Figures 6B,C. In case of the number of
osteoclasts (Figure 6B), no statistical difference was seen between
the wild type and Syk1OC cultures (p = 0.12), likely reflecting
the fact that the osteoclast numbers only declined on the last
day in the Syk1OC samples (Figure 6B). However, the number
of osteoclasts in the Syk1Haemo cultures was statistically highly
significantly reduced compared to wild type ones (p = 0.0013).
The total area covered by osteoclasts was highly significantly
reduced both by the Syk1OC (p = 0.00058) and the Syk1Haemo
(p= 0.00024) mutations.
The above results confirm prior studies indicating a critical
role for Syk during in vitro osteoclast development (40, 42, 44).
On the other hand, they also indicate an incomplete osteoclast
developmental defect in Syk1OC cultures (as opposed to the
complete defect in Syk1Haemo ones), suggesting incomplete
deletion of Syk in Syk1OC mutants.
Analysis of the in vitro Resorptive Activity
of Osteoclasts
We also attempted to test the in vitro resorbing capacity of
osteoclasts. To this end, myeloid precursors were plated on
an artificial hydroxyapatite layer and cultured in the presence
of M-CSF and RANKL (50 ng/ml each) for 7 days, followed
by assessment of hydroxyapatite resorption by dark field
microscopy. It should be noted that this assay measures the
combined effect of both osteoclast development and osteoclast-
mediated matrix resorption.
As shown in Figure 7A, wild type osteoclast cultures were
able to resorb substantial areas of the hydroxyapatite layer
(resorbed areas show a dark appearance). In contrast, only
small areas of resorption could be observed in Syk1OC cultures
and no resorption was seen in Syk1Haemo cultures (Figure 7A).
Quantification of the resorbed area revealed ∼40% resorption in
wild type cultures, which was strongly reduced by the Syk1OC and
completely eliminated by the Syk1Haemo mutations (Figure 7B).
Statistical analysis (one-way ANOVA) revealed highly significant
reduction of the resorption activity both by the Syk1OC
(p= 0.00040) and the Syk1Haemo (p= 0.00038) mutations.
These results confirm an important role for Syk in the
development and/or function of bone-resorbing osteoclasts (42),
and also indicate slight differences between the Syk1OC and
Syk1Haemo mutations.
Analysis of Osteoclast-Specific Gene
Expression
We next tested the changes of osteoclast-specific gene expression
in osteoclast cultures from the different genotypes. We have
also tested additional control macrophage cultures generated
under identical conditions except that RANKL treatment was
omitted. As shown in Figure 8, the expression of DC-STAMP
(encoded by the Tm7sf4 gene), TRAP (Acp5), calcitonin receptor
(Calcr), NFATc1 (Nfatc1) and cathepsin K (Ctsk) mRNA strongly
increased upon osteoclastic differentiation whereas no such
increase could be observed in parallel macrophage cultures. The
expression of all those genes were reduced in both the Syk1OC
and Syk1Haemo cultures (Figure 8), though the defect ranged
from a moderate (Tm7sf4) to a very strong (Calcr) reduction.
It should also be noted that the reduced expression of Ctsk in
Syk1OC samples is likely partially due to the inactivation of one
of the two alleles of the Ctsk gene by the Ctsk-Cre (CtskCre/+)
mutation present in those cells. Taken together, gene expression
data indicate a role for Syk in regulation of osteoclast-specific
gene expression.
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FIGURE 5 | Histological and immunofluorescence analysis of osteoclast-specific and hematopoietic Syk deficiency. Representative photomicrographs of the
trabecular area of the femurs of 9-week-old wild type (WT), Syk1OC or Syk1Haemo mice. (A) Haematoxylin and eosin staining; original magnification ×10. (B)
Calcitonin receptor immunostaining; original magnification × 40. Arrows indicate calcitonin receptor-positive bone lining cells (likely osteoclasts). Images are
representative of 3 mice per gender and genotype.
Analysis of Syk Protein Levels in
Osteoclast Cultures
The different severity of the in vivo bone phenotypes
(Figures 1–5) and in vitro osteoclast developmental defect
(Figure 6) between the Syk1OC and Syk1Haemo mutants raised
the possibility that Syk is incompletely deleted from Syk1OC
osteoclasts. To test this more specifically, we performed
Western Blot analysis of Syk expression during osteoclastic
and macrophage differentiation of wild type and mutant bone
marrow cells.
As shown in Figure 9A, Syk was present in all wild type
cultures and its expression slightly even increased during
osteoclast differentiation from wild type myeloid progenitors.
Importantly, Syk was also present throughout the assessment
period in Syk1OC cultures (Figure 9A). On the other hand, Syk
was completely absent throughout the entire observation period
in Syk1Haemo cultures (Figure 9A). Semiquantitative analysis of
the Western blot samples (Figure 9B) confirmed the presence of
Syk in all wild type and Syk1OC but not in Syk1Haemo samples.
Although there was a tendency of reduced Syk expression in
Syk1OC osteoclasts as compared to wild type osteoclasts, this
difference was not statistically significant, indicating that the
Syk1OC mutation is not able to reduce Syk expression at the
overall cell population level.
The above results provided direct evidence supporting our
assumption that Syk is incompletely deleted from Syk1OC but it
is completely absent from Syk1Haemo osteoclast cultures.
Genetic Analysis of Syk Deletion
During Osteoclastogenesis
One of the possible explanations for the observed differences
between the Syk1OC and Syk1Haemo mutants is that Cre
expression from the Ctsk-Cre mutation occurs at a late stage
of osteoclast development which, combined with the potentially
long survival of the Syk protein, leads to reduction of Syk protein
levels only at a late stage when osteoclast development has already
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FIGURE 6 | Analysis of in vitro osteoclast development. Bone marrow-derived myeloid progenitors from wild type (WT), Syk1OC or Syk1Haemo mice were cultured in
the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL for the indicated times, followed by staining for tartrate-resistant acid phosphatase (TRAP). (A) Representative
images of TRAP-stained cultures. (B) Quantification of the number of osteoclasts (TRAP-positive cells with 3 or more nuclei) in the different cultures. (C) The area
covered by osteoclasts in the different cultures (in % of the total culture area). Images are representative of, and bar graphs show mean and SEM from, 3 independent
experiments.
FIGURE 7 | Analysis of the in vitro resorptive function of osteoclasts. Bone marrow-derived myeloid progenitors from wild type (WT), Syk1OC or Syk1Haemo mice
were cultured in the presence of 50 ng/ml M-CSF and 50 ng/ml RANKL for 7 days on an artificial hydroxyapatite layer. (A) Representative dark-field microscopic
images of resorption pits (dark areas). (B) Quantification of the resorption area (in percent of the total area). Images are representative of, and bar graphs show mean
and SEM from, 3 independent experiments.
occurred. The fact that the substantial expression of the Ctsk gene
(encoding for cathepsin K) begins at 2 days, and is maximal at 3
days after RANKL treatment (Figure 8) (54, 55) would be in line
with that possibility.
As a first approach to address the above issue, we performed
qPCR-based analysis of the expression the Cre recombinase
in osteoclasts and macrophages from the different genotypes
(Figure 10A). As expected, no Cre expression could be observed
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FIGURE 8 | Analysis of osteoclast-specific gene expression. Gene expression in bone marrow-derived cells from wild type (WT), Syk1OC or Syk1Haemo mice
cultured for 0–3 days in the presence of 50 ng/ml M-CSF with (osteoclasts; OC) or without (macrophages; M8) 50 ng/ml RANKL. The expression of the Tm7sf4,
Acp5, Calcr, Nfatc1, and Ctsk genes (encoding for DC-STAMP, TRAP, Calcitonin receptor, NFATc1, and Cathepsin K, respectively) were determined by quantitative
RT-PCR and normalized to Gapdh. Bar graphs show mean and SEM from 3 independent experiments.
in wild type cultures. Somewhat surprisingly, no Cre mRNA
could be detected in Syk1Haemo cultures either which, together
with the complete absence of Syk protein in those cultures
(Figure 9) suggests that the Vav-Cre transgene is activated
at an early stage of hematopoiesis but it is silenced at the
stage of myeloid differentiation tested in our experiments. On
the other hand, Cre expression could be readily observed in
Syk1OC osteoclast but not macrophage cultures (Figure 10A).
Importantly, substantial Cre expression in Syk1OC osteoclasts
was first observed 2 days after the initial RANKL treatment, and
continued afterwards. Given that a longer time may be needed to
the effective deletion of both Syk alleles, the supposedly partial
deletion efficacy of the Ctsk-Cre transgene and that the Syk
mRNA and protein likely does not immediately disappear after
the Cre-mediated inactivation of the Syk gene, these results are
in line with the continued presence of Syk in Syk1OC osteoclasts
beyond 2 days after the initial RANKL administration (Figure 9).
As a more direct approach to test Cre-mediated deletion of
Syk in our osteoclast cultures, we decided to perform PCR-
based analysis of the Syk genomic locus from the cells of
our various genotypes. To this end, we first amplified and
sequenced the genomic DNA around the two loxP insertion
sites, which was used along with the publicly available mouse
genomic sequence and the original description of the Sykflox
mutation (50) to reconstruct the entire sequence of the
Sykflox allele (Supplementary Figure 1). The organization of the
Syk+ (wild type), Sykflox and Syk1 (result of Cre-mediated
deletion) alleles is shown in Supplementary Figure 2, indicating
the inserted loxP and other sequences, as well as the sites
and results of Cre-mediated recombination. Based on this
organization, we have designed two PCR protocols (termed
PCR 1 and PCR 2) to amplify specific alleles from genomic
DNA (Supplementary Figure 2). PCR 1 (Figure 10B and
Supplementary Figure 2) was our standard genotyping PCR
protocol using the P fwd and P rev1 primer pair, and was able
to distinguish between the Syk+ and the Sykflox allele, based on
the increased length of the PCR product caused by the 115 bp
insertion during the generation of the Sykflox allele (49). However,
PCR 1 was not able to detect the deleted (Syk1) allele because the
sequence corresponding to the P rev1 primer was deleted during
Cre-mediated excision of the floxed sequences from the Sykflox
allele (Supplementary Figure 2). Therefore, we designed a novel
PCR protocol (PCR 2; Figure 10C and Supplementary Figure 2)
using the same P fwd forward primer along with a new P rev2
reverse primer, spanning the entire floxed sequence, allowing
the simultaneous detection of all three (Syk+, Sykflox, and Syk1)
alleles. We then cultured wild type, Syk1OC and Syk1Haemo bone
marrow cells in the presence of M-CSF and RANKL for different
periods of time and analyzed their genomic DNA with both the
PCR 1 (Figure 10B) and PCR 2 (Figure 10C) protocols.
Results with PCR 1 are shown in Figure 10B. In line with
our expectations, the Syk+ allele was present throughout the
assay period in wild type osteoclast cultures and the Sykflox
allele was present in all Syk1OC samples. Though the latter
finding indicated the presence of the non-recombined Sykflox
allele throughout osteoclast development, it did not exclude
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FIGURE 9 | Analysis of the level of Syk protein in osteoclast and macrophage
cultures. Bone marrow-derived myeloid progenitors from wild type (WT),
Syk1OC or Syk1Haemo mice were cultured in the presence of 50 ng/ml M-CSF
with (osteoclasts; OC) or without (macrophages; M8) 50 ng/ml RANKL for the
indicated times. Whole-cell lysates were then prepared and processed for
immunoblotting for Syk, or for actin as a loading control. Representative
immunoblots (A) or quantification of Syk/actin ratios normalized to Day 1 OC
(B) are shown. Blots are representative of, and bar graphs show mean and
SEM from, 3 to 6 independent experiments.
substantial deletion (reduction) of the Sykflox allele given the
tendency of PCR to amplify even small amounts of the target
templates when no competing templates are present. In contrast,
neither the Syk+ nor the Sykflox allele could be amplified
from Syk1Haemo cultures (Figure 10B), suggesting complete
deletion of the Sykflox allele from those cells, likely in an
earlier stage of hematopoietic development. Unfortunately, the
Syk1 allele could not be detected with the PCR 1 protocol
(Figure 10B and Supplementary Figure 2).
Results with PCR 2 (which could detect all three alleles
including the Syk1 allele; see Supplementary Figure 2) is shown
in Figure 10C. Those experiments confirmed the expected
exclusive presence of the Syk+ allele throughout the experiment
in wild type cultures, as well as the exclusive presence of the Syk1
allele throughout the Syk1Haemo samples, indicating complete
deletion of the Sykflox allele in the Syk1Haemo cultures. In contrast
to the static picture in wild type and Syk1Haemo cultures, the
Syk1OC cultures showed dynamic changes in the Syk locus
(Figure 10C). While only the Sykflox allele was seen 1 day after
the initial RANKL treatment, the Syk1 allele appeared and its
amount gradually increased during the next 3 days, parallel to
a proportional decline (but not complete disappearance) of the
Sykflox allele (Figure 10C). It should be noted that the appearance
of the smaller-size Syk1 allele likely had a competitive advantage
over the larger-size Sykflox allele in these PCR reactions, leading
to a likely underestimation of the amount of the Sykflox allele.
Taken together, those results and the time course of the changes
indicate that Ctsk-Cre-mediated deletion of the Sykflox allele
occurs gradually during 2–4 days after RANKL addition and that
only an incomplete genetic deletion of Syk is achieved even until
the end of the observation period.
The above results indicate slow and gradual deletion of
the Sykflox allele in Syk1OC osteoclast cultures, which is in
line with the slow activation of the Ctsk gene during in vitro
osteoclast development (Figures 8, 10A) (54, 55). These results
may also explain the less severe in vivo phenotypes (Figures 1–5)
and less pronounced in vitro osteoclast developmental defect
(Figure 6), as well as the continuous presence of Syk in osteoclast
cultures (Figure 9), in the Syk1OC mutants, as compared with
the Syk1Haemo mutants which show early and complete deletion
of the Sykflox allele from the beginning of the entire osteoclast
developmental process.
Analysis of Myeloid-Specific Syk Deletion
Osteoclasts are derived from early myeloid progenitors through a
developmental process related to that of macrophages. Therefore,
we have also tested certain aspects of osteoclast biology
in Syk1Myelo mutants in which Syk is conditionally deleted
using the myeloid-specific LysM-Cre knock-in mutation. The
Syk1Myelo mutation strongly reduced (but did not completely
abrogate) osteoclast development, both in terms of the
number of osteoclasts (Supplementary Figure 3A) and the area
covered by osteoclasts (Supplementary Figure 3B). As shown in
Supplementary Figure 3C, Syk expression was strongly reduced
(but did not completely disappear) in both Syk1Myelo osteoclasts
and macrophages. The Syk1Myelo mutation also partially reduced
osteoclast-specific gene expression, i.e., the upregulation of
the mRNA of the Tm7sf4, Acp5, Calcr, Nfatc1, and Ctsk
genes (Supplementary Figure 3D). We have also tested Cre
expression in wild type and Syk1Myelo cells. As shown in
Supplementary Figure 3D, Cre mRNA was absent from wild
type cells but it was expressed in all Syk1Myelo samples.
Interestingly, Cre expression was especially high in early myeloid
progenitors (Day 0 samples) and declined afterwards both
in osteoclast and macrophage cultures. Taken together, the
Syk1Myelo mutation leads to strong but incomplete deletion of
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FIGURE 10 | Genetic analysis of Cre expression and Cre-mediated Syk deletion. (A) Cre expression in wild type (WT), Syk1OC or Syk1Haemo mice bone
marrow-derived cells cultured for 0–3 days in the presence of 50 ng/ml M-CSF with (osteoclasts; OC) or without (macrophages; M8) 50 ng/ml RANKL. Bar graph
shows mean and SEM from 3 independent experiments. (B,C) PCR analysis of wild type (WT), Syk1OC or Syk1Haemo osteoclast cultures (differentiated in the
presence of 50 ng/ml RANKL and M-CSF for 1–4 days) using PCR 1 (P fwd vs. P rev1 primers; B) or PCR 2 (P fwd vs. P rev2 primers; C). Images are representative of
4 independent experiments.
Syk during early myeloid differentiation, leading to strongly
reduced but not completely abrogated in vitro development
of osteoclasts.
DISCUSSION
In this manuscript, we provide direct genetic evidence for the
role of the Syk tyrosine kinase in normal bone homeostasis in
adult mice. The perinatal lethality of Syk−/− mice was overcome
by lineage-specific conditional deletion of Syk in osteoclasts
(Syk1OC mice) or in the entire hematopoietic system (Syk1Haemo
mice). Both osteoclast-specific and hematopoietic Syk deletion
led to increased trabecular bone mass and defective in vitro
osteoclast development and function. However, hematopoietic
Syk deletion caused more robust changes than osteoclast-specific
Syk deletion both in vivo and in vitro. Our results suggest that
this is due to late and incomplete deletion of Syk in osteoclast-
specific Syk mutants, likely caused by late activation and modest
activity of Cre expression driven by the Ctsk gene promoter
during osteoclast development.
We and others have previously shown that Syk plays an
important role in in vitro osteoclast development and osteoclast-
mediated resorptive activity (40, 42, 44). However, the role of Syk
in bone homeostasis in live mice could not be tested because
of the perinatal lethality of Syk−/− mice (17, 18), although
bone density appeared to be increased in third-trimester Syk−/−
fetuses (44). Unfortunately, the in vitro osteoclast phenotypes
cannot be directly extrapolated to the in vivo situation since a
number of mutations even within the same pathway, such as
DAP12 (38, 41–43) or PLCγ2 (54, 58, 59) deficiency, provide
examples of practically complete in vitro osteoclast defects
despite only moderately increased in vivo bone mass. Our in vivo
results, especially those with the Syk1Haemo mice, provide the first
direct genetic evidence for a major and critical role of Syk in bone
homeostasis in live animals.
The two main models used in this study clarify different
aspects of the role of Syk in bone metabolism: the Syk1OC mice
provide evidence for an osteoclast-specific role of Syk but it only
leads to limited defects, while the Syk1Haemo mice have the widest
Syk deletion without embryonic lethality and therefore show the
maximum extent of bone resorption defects.
Despite the clear in vivo phenotypes of conditional Syk-
deficient mice, a number of questions related to the cell type(s)
responsible remain open. Our experiments with the Syk1OC mice
indicate that the role of Syk in bone metabolism is at least
in part mediated by Syk expression in osteoclasts. However, it
is at present unclear why Syk1Haemo mice have a more severe
phenotype than the Syk1OC animals. A reasonable explanation,
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also supported by our in vitro findings, is that the Syk1OC
mutation only partially deletes Syk in the osteoclast lineage
(see further discussion below). However, we cannot exclude the
possibility that changes to (a) hematopoietic lineage(s) other than
osteoclasts in the Syk1Haemo mice also contribute to the increased
bone mass. In addition, it is also possible that Syk deletion in
osteoclasts and/or other hematopoietic cells indirectly promote
osteoblast-mediated bone production. It should be mentioned
that prior studies (44) showed normal bone production by
Syk−/− osteoblasts, therefore it is unlikely that Syk deficiency in
osteoblasts (e.g., through a leaky Cre expression) contributes to
the observed in vivo bone phenotypes. It should also be noted
that our micro-CT studies indicate increased trabecular number
rather than a higher trabecular thickness as the main cause of
the in vivo bone phenotypes. Unfortunately, different groups
have reported different contributions of the changes of trabecular
number and trabecular thickness to increased bone mass linked
to osteoclast defects (42, 43, 54, 55), making it rather difficult
to determine the contribution of osteoclasts and osteoblasts to a
bone phenotype based on micro-CT data.
An interesting question arising from this study is why the
Syk1OC mutation causes a less severe osteoclast phenotype than
the Syk1Haemo mutation. Our results clearly indicate that the
Syk1OC mutation is less effective in inactivating the Syk gene in
osteoclasts. One possible explanation is the fact that the Ctsk-Cre
mutation triggers Cre activation at a relatively later time point
(starting at ∼2 days after RANKL treatment) which, combined
with the likely continued presence of the preexisting Syk mRNA
and Syk protein beyond complete deletion of both Syk alleles,
may lead to a late disappearance of the Syk protein at a time point
where osteoclast development and osteoclast-mediated bone
resorption has already occurred. The activation kinetics of the
Ctsk gene (Figure 8) and of the Ctsk-Cre mutation (Figure 10A),
as well as the late appearance of the Syk1 allele (Figure 10C) all
support this explanation. Another possible explanation is that the
level of Cre expression from the Ctsk-Cre mutation is too low to
provide complete Syk deletion and therefore a significant amount
of Syk remains present even after activation of the Ctsk-Cre
mutation. In this respect, it is interesting to see that themaximum
level of Cre expression in Syk1OC cultures (Figure 10A) is at least
an order of magnitude less than that in the Syk1Myelo cultures
(Supplementary Figure 3D). Nevertheless, both scenarios and
our own results are consistent with prior reports from the
literature showing good specificity but incomplete deletion of
target genes (incomplete penetrance) by the Ctsk-Cre mutation
(54, 55, 60). Those results also point to the fact that the suitability
of Cre-expressing mouse strains for the lineage-specific deletion
of floxed alleles depends not only on the specificity of the Cre
expression but also on its timing, i.e., whether sufficient time is
available for nearly complete deletion of the target gene.
Though the main message of our manuscript is the increased
in vivo bone mass upon conditional deletion of Syk in live
mice, some of our results also address the mechanism of the
contribution of Syk to osteoclast development and function.
While osteoclast-specific gene expression was reduced in Syk1OC
and Syk1Myelo cultures, it was not completely abrogated even
in Syk1Myelo cells which practically completely lacked Syk
protein expression. Therefore, Syk may not only be involved
in osteoclast-specific gene expression but maybe also in later
processes such as (pre)osteoclast fusion or the osteoclast-
mediated resorption process. It is particularly interesting in
this respect that DC-STAMP was only moderately affected
by Syk deletion, suggesting that a possible role of Syk in
(pre)osteoclast fusion may rely on mechanisms other than DC-
STAMP expression. It is also worth noting that practically
complete defect of matrix resorption was seen in both Syk1OC
and Syk1Myelo cultures (i.e., no substantial difference between the
two mutations could be seen in this assay), which, however, is
complicated by the fact that this assay measures both osteoclast
development and the resorptive activity of the cells, and that
the longer culture period could have allowed more complete Syk
deletion by the Ctsk-Cre mutation. It is also of interest why the
number of osteoclasts are reduced on Day 3.5 in the Syk1OC
cultures (Figure 6). This may be simply due to the fusion of the
cells reducing the number of individual osteoclasts, apoptotic
disappearance of osteoclasts during this late stage of culture,
and/or active deletion of Syk toward that time period.
We and others have shown that Syk is required for the
development of autoantibody-induced arthritis in experimental
mice (24, 33–35) and Syk has been proposed as a therapeutic
target in human rheumatoid arthritis (61–63). A possible
role for Syk in various immune and other cells such as
neutrophils, macrophages, mast cells or even platelets (16, 22–
24, 26–29, 31, 64–67) may provide an explanation for this
observation. Nevertheless, it is important to note that both
murine arthritis models (33) and human rheumatoid arthritis
(5) are accompanied with bone erosions. Therefore, the role of
Syk in osteoclast-mediated in vivo bone resorption may also
provide an additional cell type beyond immune/inflammatory
cells in which Syk inhibitors may have a beneficial therapeutic
effect. In addition, Syk-mediated bone resorption may also be a
therapeutic target in other diseases characterized by osteoclast-
mediated bone resorption such as osteoporosis (4) or osteolytic
cancer metastases (7, 8).
Taken together, our results provide direct genetic evidence
for the role of Syk in in vivo bone metabolism and therefore
may contribute to the rationale of developing Syk inhibitors
for the treatment of diseases characterized by pathologic
bone loss.
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andMócsai. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 16 April 2019 | Volume 10 | Article 937
